Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Last trade$5.53
Day change-$0.35 (-5.95%)
Day range$5.50 – $6.00
Volume488,700
Market cap$478M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$477.99M
Price / earnings
—
Price / book
-1.37×
Price / sales
1.74×
EV / sales
1.68×
EV / EBITDA
-18.43×
Profitability
Earnings per share
-$1.02
Return on assets
-24.06%
Return on equity
23.87%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.48×
Current ratio
1.76×
Quick ratio
1.72×
Cash ratio
1.06×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PHAT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$84.72M
$74.27M
$58.3M
$57.58M
$49.5M
$39.5M
$28.52M
$29.66M
Cost of revenue
$18.37M
$15.1M
$12M
$7.65M
$6.19M
$5.04M
$3.72M
$3.82M
Gross profit
$66.36M
$59.18M
$46.31M
$49.94M
$43.31M
$34.47M
$24.8M
$25.85M
Selling, general and administrative
$57.7M
$55.33M
$54.01M
$48.37M
$51.56M
$85.31M
$94.47M
$76.68M
Research and development
$8.75M
$7.81M
$7.77M
$7.49M
$7.03M
$9.08M
$9.18M
$8.58M
Total operating expenses
$66.44M
$63.14M
$61.78M
$55.86M
$58.59M
$94.39M
$103.66M
$85.27M
Operating income
-$85K
-$3.97M
-$15.48M
-$5.93M
-$15.27M
-$59.92M
-$78.86M
-$59.42M
Interest expense
-$15.39M
-$15.1M
-$15.8M
-$16.42M
-$16.11M
-$17.52M
-$18.07M
-$18.59M
Income before taxes
-$13.9M
-$17.58M
-$30.37M
-$21.15M
-$29.97M
-$75.81M
-$94.32M
-$74.45M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$13.9M
-$17.58M
-$30.37M
-$21.15M
-$29.97M
-$75.81M
-$94.32M
-$74.45M
Net income attributable to common shareholders
-$13.9M
-$17.58M
-$30.37M
-$21.15M
-$29.97M
-$75.81M
-$94.32M
-$74.45M
EBITDA
$35K
-$3.85M
-$15.37M
-$5.8M
-$15.12M
-$59.75M
-$78.69M
-$59.22M
Basic earnings per share
-$0.16
-$0.21
-$0.37
-$0.29
-$0.41
-$1.05
-$1.31
-$1.05
Diluted earnings per share
-$0.16
-$0.21
-$0.37
-$0.29
-$0.41
-$1.05
-$1.31
-$1.05
Recent news
Company coverage with links to the original publishers.
Phathom Pharmaceuticals (PHAT) is experiencing high implied volatility in its January 2027 $30 call options, suggesting traders expect significant price movement. However, the company holds a Zacks Rank #4 (Sell) rating, with analysts downgrading earnings estimates for the current quarter from 15 cents to 12 cents per share over the last 30 days. The elevated volatility may present opportunities for options traders to sell premium and capture decay.
Phathom Pharmaceuticals announced that its management team will participate in three major investor conferences in November 2026: Guggenheim 3rd Annual Healthcare Innovation Conference (Nov 10), Stifel 2026 Healthcare Conference (Nov 11), and Jefferies Global Healthcare Conference (Nov 18). The company will host fireside chats and one-on-one meetings at each event, with live webcasts and 90-day archived recordings available.
Phathom Pharmaceuticals announced that the FDA established a public docket to solicit comments on regulatory questions regarding BDR Pharmaceuticals' challenge to VOQUEZNA's 10-year New Chemical Entity (NCE) exclusivity, which is set to expire May 3, 2032. Phathom plans to intervene in the litigation and submit comments to defend its statutory exclusivities. A second ANDA filer, Saba Ilac, has also indicated intent to consolidate its case with BDR's.
BDR Pharmaceuticals filed suit against the FDA challenging the agency's application of the GAIN Act to extend Phathom Pharmaceuticals' New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan) through May 2032. Phathom believes the FDA correctly evaluated the issue and intends to defend its statutory exclusivities.
Phathom Pharmaceuticals announced that its management team will participate in two major investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. Both events will feature fireside chats and one-on-one meetings with investors. Live webcasts and 90-day archived recordings will be available on the company's investor relations website.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.